{"id":"venetoclax-decitabine-azacitidine-aclarubicin-association","safety":{"commonSideEffects":[{"rate":"50-70%","effect":"Neutropenia"},{"rate":"30-50%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Venetoclax's mechanism of action involves binding to BCL-2, preventing its anti-apoptotic function, and thereby promoting cell death. Decitabine/Azacitidine-Aclarubicin combination induces DNA hypomethylation, leading to the reactivation of tumor suppressor genes and the promotion of apoptosis in cancer cells.","oneSentence":"Venetoclax targets and inhibits BCL-2, a protein that prevents apoptosis, while Decitabine/Azacitidine-Aclarubicin combination works by inducing DNA hypomethylation and promoting apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:50.028Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML)"}]},"trialDetails":[{"nctId":"NCT05264883","phase":"PHASE3","title":"Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-03-01","conditions":"Acute Myeloid Leukemia","enrollment":170}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Venetoclax-Decitabine/Azacitidine-Aclarubicin Association","genericName":"Venetoclax-Decitabine/Azacitidine-Aclarubicin Association","companyName":"The First Affiliated Hospital with Nanjing Medical University","companyId":"the-first-affiliated-hospital-with-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Venetoclax targets and inhibits BCL-2, a protein that prevents apoptosis, while Decitabine/Azacitidine-Aclarubicin combination works by inducing DNA hypomethylation and promoting apoptosis in cancer cells. Used for Acute myeloid leukemia (AML).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}